Lexicon Pharma (LXRX) Tops Q3 EPS by 7c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.47 +0.68%
EPS Growth %: -50.0%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: -50.0%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.29), $0.07 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $26.94 million versus the consensus estimate of $27.96 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
